Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.

Nelson AW, Schrock AB, Pavlick DC, Ali SM, Atkinson EC, Chachoua A.

J Thorac Oncol. 2019 Feb;14(2):e27-e29. doi: 10.1016/j.jtho.2018.10.160. No abstract available.

PMID:
30683294
2.

Radiotherapy induces responses of lung cancer to CTLA-4 blockade.

Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, Heguy A, Imai N, Gnjatic S, Emerson RO, Zhou XK, Zhang T, Chachoua A, Demaria S.

Nat Med. 2018 Dec;24(12):1845-1851. doi: 10.1038/s41591-018-0232-2. Epub 2018 Nov 5.

3.

Percutaneous Cryoablation for the Management of Chronic Pain Secondary to Locally Recurrent Rectal Cancer with Bowel and Nerve Root Involvement.

Cornman-Homonoff J, Formenti SC, Chachoua A, Madoff DC.

J Vasc Interv Radiol. 2018 Sep;29(9):1296-1298. doi: 10.1016/j.jvir.2018.02.022. No abstract available.

PMID:
30146202
4.

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma.

Cordova C, Chi AS, Chachoua A, Kondziolka D, Silverman JS, Shepherd TM, Jain R, Snuderl M.

J Thorac Oncol. 2017 Nov;12(11):e188-e190. doi: 10.1016/j.jtho.2017.07.029. No abstract available.

5.

Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases.

Wolf A, Donahue B, Silverman JS, Chachoua A, Lee JK, Kondziolka D.

J Neurooncol. 2017 Aug;134(1):139-143. doi: 10.1007/s11060-017-2497-6. Epub 2017 May 23.

PMID:
28536993
6.

Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery.

Wolf A, Kvint S, Chachoua A, Pavlick A, Wilson M, Donahue B, Golfinos JG, Silverman J, Kondziolka D.

J Neurosurg. 2018 Jan;128(1):23-31. doi: 10.3171/2016.10.JNS161036. Epub 2017 Feb 17.

PMID:
28298015
7.

Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.

Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Levy BP.

Clin Lung Cancer. 2017 Jan;18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008. Epub 2016 Oct 5.

PMID:
28029530
8.

Reactivation of pulmonary tuberculosis during cancer treatment.

Jacobs RE, Gu P, Chachoua A.

Int J Mycobacteriol. 2015 Dec;4(4):337-40. doi: 10.1016/j.ijmyco.2015.05.015. Epub 2015 Jul 18.

9.

Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.

Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, Chen Z, Feld R, Cho J, Gadgeel S, Wozniak A, Chachoua A, Leighl N, Tsao MS, de Perrot M, Xu W, Liu G.

J Thorac Oncol. 2016 Jun;11(6):900-9. doi: 10.1016/j.jtho.2016.02.006. Epub 2016 Feb 21.

10.

Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.

Shin SM, Cooper BT, Chachoua A, Butler J, Donahue B, Silverman JS, Kondziolka D.

J Neurooncol. 2016 Feb;126(3):483-91. doi: 10.1007/s11060-015-1986-8. Epub 2015 Oct 31.

PMID:
26520640
11.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R.

Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14.

12.

Trileaflet mitral valve associated with a bicuspid aortic valve.

Chachoua A, Abboub B, Ghemri S, Hammoudi N.

J Cardiol Cases. 2015 Aug 21;13(2):37-39. doi: 10.1016/j.jccase.2015.08.002. eCollection 2016 Feb.

13.

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC.

Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18.

PMID:
26095785
14.

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC.

Cancer Immunol Res. 2013 Dec;1(6):365-72. doi: 10.1158/2326-6066.CIR-13-0115.

15.

Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

Dutcher JP, Neuberg D, Atkins MB, Tester WJ, Wadler S, Stewart JA, Chachoua A, Schuchter LM.

J Interferon Cytokine Res. 2014 May;34(5):376-84. doi: 10.1089/jir.2013.0010. Epub 2014 Jan 16.

16.

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.

Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ.

Cancer Biol Ther. 2013 Jul;14(7):557-63. doi: 10.4161/cbt.24598. Epub 2013 May 10.

17.

Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?

Marquez-Medina D, Chachoua A, Martin-Marco A, Desai AM, Garcia-Reglero V, Salud-Salvia A, Muggia F.

Clin Transl Oncol. 2013 Nov;15(11):959-64. doi: 10.1007/s12094-013-1035-z. Epub 2013 Apr 20.

PMID:
23606352
18.

CT scan screening for lung cancer: risk factors for nodules and malignancy in a high-risk urban cohort.

Greenberg AK, Lu F, Goldberg JD, Eylers E, Tsay JC, Yie TA, Naidich D, McGuinness G, Pass H, Tchou-Wong KM, Addrizzo-Harris D, Chachoua A, Crawford B, Rom WN.

PLoS One. 2012;7(7):e39403. doi: 10.1371/journal.pone.0039403. Epub 2012 Jul 2.

19.

The management of EGFR inhibitor adverse events: a case series and treatment paradigm.

Wnorowski AM, de Souza A, Chachoua A, Cohen DE.

Int J Dermatol. 2012 Feb;51(2):223-32. doi: 10.1111/j.1365-4632.2011.05082.x.

PMID:
22250636
20.

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC.

Ballas MS, Chachoua A.

Onco Targets Ther. 2011;4:43-58. doi: 10.2147/OTT.S18155. Epub 2011 May 30.

21.

The appearance of cardiac metastasis from squamous cell carcinoma of the lung on F-18 FDG PET/CT and post hoc PET/MRI.

Probst S, Seltzer A, Spieler B, Chachoua A, Friedman K.

Clin Nucl Med. 2011 Apr;36(4):311-2. doi: 10.1097/RLU.0b013e31820a9fd1. No abstract available.

PMID:
21368610
22.

Increasing dyspnea due to an anterior mediastinal mass.

Alpert JB, Nonaka D, Chachoua A, Pass HI, Ko JP.

Chest. 2011 Jan;139(1):217-23. doi: 10.1378/chest.10-0383. No abstract available.

PMID:
21208885
23.

Azygos venous tumor thrombus from renal cell carcinoma detected by F-18 FDG PET/CT.

Probst S, Seltzer A, Chachoua A, Friedman K.

Clin Nucl Med. 2010 Oct;35(10):832-3. doi: 10.1097/RLU.0b013e3181ef0bae.

PMID:
20838303
24.

Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer.

Sanfilippo NJ, Taneja SS, Chachoua A, Lepor H, Formenti SC.

J Clin Oncol. 2008 Jun 20;26(18):2973-8. doi: 10.1200/JCO.2007.14.4105.

PMID:
18565883
25.

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM.

J Clin Oncol. 2005 Sep 1;23(25):6107-16.

PMID:
16135477
26.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P.

J Clin Oncol. 2004 Aug 15;22(16):3238-47.

PMID:
15310767
27.

Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.

Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F.

J Clin Oncol. 2003 Jul 15;21(14):2703-7.

PMID:
12860947
28.

A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.

Sewak S, Chachoua A, Hamilton A, Taneja S, Lee J, Utate M, Sorich J, Muggia FM.

Anticancer Drugs. 2003 Jan;14(1):67-72.

PMID:
12544260
29.

TIA-1+ cytotoxic large T-cell lymphoma of the mediastinum: case report.

Yang GC, Yee HT, Wu CD, Aye LM, Chachoua A.

Diagn Cytopathol. 2002 Mar;26(3):154-7.

PMID:
11892019
30.

A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.

Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F.

Cancer. 2001 Jun 1;91(11):2039-45.

PMID:
11391583
31.

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ.

Clin Cancer Res. 2001 Apr;7(4):800-5.

32.

Prostatic adenocarcinoma metastatic to the breasts: report of a case with diagnosis by fine needle aspiration biopsy.

Yan Z, Hummel P, Waisman J, Newstead GM, Chachoua A, Chhieng D, Cohen JM, Cangiarella J.

Urology. 2000 Apr;55(4):590.

PMID:
10754179
33.

Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.

Rosenthal MA, Dennis D, Liebes L, Furmanski P, Caron D, Garrison L, Wiprovnick J, Peace D, Oratz R, Speyer J, Chachoua A.

J Immunother. 1998 Sep;21(5):371-8.

PMID:
9789199
34.

Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.

Gottlieb JJ, Washenik K, Chachoua A, Friedman-Kien A.

Lancet. 1997 Nov 8;350(9088):1363-4. No abstract available.

PMID:
9365453
35.

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.

Clin Cancer Res. 1997 Aug;3(8):1245-52.

36.

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J.

J Clin Oncol. 1996 Jul;14(7):1993-9. Erratum in: J Clin Oncol 1996 Dec;14(12):3175.

PMID:
8683229
37.

Fusion of immunoscintigraphy single photon emission computed tomography (SPECT) with CT of the chest in patients with non-small cell lung cancer.

Katyal S, Kramer EL, Noz ME, McCauley D, Chachoua A, Steinfeld A.

Cancer Res. 1995 Dec 1;55(23 Suppl):5759s-5763s.

38.

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.

Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH.

J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):132-41.

PMID:
7804528
39.

Extension of a secondary adrenal neoplasm into the inferior vena cava.

Gollub MJ, Bosniak MA, Schlossberg P, Chachoua A.

Abdom Imaging. 1994 Jul-Aug;19(4):359-60.

PMID:
8075565
40.

Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor.

Chachoua A, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, Blum RH, Vilcek J.

J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):217-24.

PMID:
8032545
41.

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al.

J Clin Oncol. 1994 Mar;12(3):553-9.

PMID:
8120553
42.

Kaposi's sarcoma.

Cho J, Chachoua A.

Curr Opin Oncol. 1992 Aug;4(4):667-73. Review. Erratum in: Curr Opin Oncol 1992 Oct;4(5):999.

PMID:
1380838
43.

Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.

Liebes L, Walsh CM, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, Le Sher D, et al.

J Natl Cancer Inst. 1992 May 6;84(9):694-9.

PMID:
1569602
44.

Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's sarcoma (AIDS-KS).

Chachoua A, Green M, Wernz J, Muggia F.

Invest New Drugs. 1989 Nov;7(4):327-31.

PMID:
2513285
45.

Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.

Beller U, Chachoua A, Speyer JL, Sorich J, Dugan M, Liebes L, Hayes R, Beckman EM.

Gynecol Oncol. 1989 Sep;34(3):407-12.

PMID:
2788602
46.

Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma.

Chachoua A, Krigel R, Lafleur F, Ostreicher R, Speer M, Laubenstein L, Wernz J, Rubenstein P, Zang E, Friedman-Kien A.

J Clin Oncol. 1989 Jun;7(6):774-80.

PMID:
2565954
47.

Phase I study of the combination of alpha-2 interferon and cisplatinum.

Walsh C, Speyer JL, Wernz J, Hochster H, Grossberg H, Chachoua A, Molinaro P, Meyers M, Blum RH.

J Biol Response Mod. 1989 Feb;8(1):11-5.

PMID:
2921608
48.

Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome.

Chachoua A, Green MD, Valentine F, Muggia FM.

Cancer Invest. 1989;7(3):225-9.

PMID:
2790539
49.

Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS.

Dieterich DT, Chachoua A, Lafleur F, Worrell C.

Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S532-7.

PMID:
2847290
50.

Oral candidiasis and AIDS.

Chaudhry AP, Chachoua A, Saltzman BR, Friedman-Kien A.

J Am Dent Assoc. 1988 Jun;116(7):818, 820. No abstract available.

PMID:
3164734

Supplemental Content

Loading ...
Support Center